It has been an eventful weeks in pharma and biotech news so far in 2026. Here is a guide to every major story and what it means.

Novartis and Bristol Myers CAR-T Safety Halts

What happened?

Both Novartis and Bristol Myers Squibb paused multiple trials of their CAR-T cell therapies in autoimmune diseases after worrisome safety incidents. Novartis instituted program-wide clinical holds across eight trials of Rap-cel in lupus, myasthenia gravis, multiple sclerosis, and other autoimmune conditions after three cases of immune effector cell-associated hemophagocytic syndrome — a rare and potentially life-threatening reaction — led to fatal outcomes. Bristol Myers voluntarily paused enrollment in its autoimmune trials of zolacabtagene autoleucel (Zola-cel) after detecting transient and reversible inflammatory events during routine safety surveillance, though it did not halt the studies outright.

Are these the same kind of safety event?

Not exactly. Novartis reported three cases of IEC-HS with fatal outcomes — a serious signal that prompted a comprehensive program-wide review. Bristol Myers described its events as transient and reversible, pausing enrollment out of an abundance of caution while maintaining confidence in its drug's known safety profile. The company noted that one case of IEC-HS had already been disclosed from a prior Phase I study, and that Zola-cel has demonstrated "transformational, treatment-free responses" in SLE and other autoimmune diseases.

Why are analysts pointing to manufacturing speed as a possible cause?

Both Rap-cel and Zola-cel use technology designed to compress production timelines compared with earlier CAR-T products. William Blair analyst Sami Corwin noted that the faster cell-growth approach "could be driving increased cell expansion and the reported toxicities," though she cautioned that other factors may be involved. Companies including Cabaletta Bio, Kyverna Therapeutics, and Autolus Therapeutics, which use more traditional manufacturing processes, saw their shares drop sharply on the news before recovering — suggesting investors are trying to determine whether the safety signal is platform-specific or modality-wide.

What does this mean for the broader autoimmune CAR-T field?

The scale of Novartis's pause — eight trials suspended simultaneously — has drawn particular investor attention and raised wider questions about the safety profile of the entire platform. Kyverna Therapeutics has a potential filing in stiff person syndrome by year-end and is enrolling patients in a pivotal myasthenia gravis study. Cabaletta Bio has multiple trials underway including a late-stage myositis study. Whether these events slow the field's momentum or are ultimately attributed to a specific manufacturing approach will be one of the most closely watched questions in immunology over the next several months.

Ultragenyx and the Angelman Syndrome Trial Failure

What happened?

Ultragenyx shares fell more than 40% after apazunersen failed to meet both its primary endpoint — improving cognitive and nonverbal reasoning skills — and its secondary integrated multi-domain responder endpoint in the Phase 3 Aspire trial for Angelman syndrome. The trial showed no treatment-placebo difference supportive of efficacy. There are currently no approved disease-modifying treatments for Angelman syndrome, which occurs in about 1 in 15,000 live births.

Is this Ultragenyx's first late-stage setback?

No. This marks the company's second consecutive late-stage trial failure, which Jefferies analyst Maury Raycroft called "unambiguously negative" and likely to "further erode street confidence." The investment case has changed materially — Leerink Partners analyst Joseph Schwartz says Ultragenyx is now "a commercial and expense story rather than a pipeline execution story." The company says it will implement significant expense reductions.

What happens to the Angelman program now?

Ultragenyx is reviewing the program's future and deciding on its disposition. William Blair analyst Sami Corwin warned that even if the company's separate Aurora study — testing apazunersen in Angelman patients with other genotypes — meets its primary endpoint, "commercialization will be challenging given the limited size of the addressable population."

What does this mean for competitors?

Jefferies noted that the Aspire failure "raises risk for competitors" including Ionis Pharmaceuticals and Oak Hill Bio, which are developing similar treatments for Angelman syndrome. The failure raises questions about whether the issue is specific to apazunersen, broader to ASO delivery in this population, or reflective of fundamental challenges in measuring efficacy in rare neurodevelopmental diseases with small, heterogeneous patient populations.

What else is happening at Ultragenyx?

Not everything is negative. Last month, Ultragenyx's gene therapy Genglycos became the first to receive FDA approval to treat Von Gierke disease, a rare metabolic disorder — a meaningful regulatory win that partially offset the pipeline setback.

Simcere Zaiming and Roche's $1.53 Billion SIM0660 Deal

What is SIM0660?

SIM0660 is a first-in-class tri-specific antibody developed by Simcere Zaiming using its T-cell engager poly-specific antibody technology. The molecule combines a CD3-engaging arm with binding domains targeting two B-cell antigens — CD79a and CD19 — to induce potent T-cell-mediated cytotoxicity while limiting cytokine release. The dual B-cell antigen targeting approach has not previously reached this stage of development.

Why does targeting both CD79a and CD19 matter?

By targeting two B-cell antigens rather than one, SIM0660 is designed to provide broader coverage across B-cell populations relevant to both B-cell malignancies and autoimmune disease, and may offer a differentiated therapeutic approach for patients who have already been treated with CD20- or CD19-directed therapies. Its cytokine-limiting design also aims to address a known tolerability challenge for T-cell engager therapies.

What are the deal terms?

Roche receives exclusive global rights to develop, manufacture, and commercialize SIM0660. Simcere Zaiming is eligible for up to $1.53 billion in total payments — including $75 million upfront — plus tiered double-digit royalties on future net sales. The payment structure weights the bulk of the deal's value toward future development, regulatory, and commercial milestones.

What does this deal mean for Simcere's broader strategy?

This is Simcere Pharmaceutical Group's sixth major out-licensing transaction, with potential aggregate consideration now exceeding $6.1 billion. The Roche agreement confirms that Simcere's T-cell engager poly-specific antibody platform — the same technology underlying SIM0660 — is generating sustained global commercial interest. Incubate executive director John Stanford, who spoke with Pharmaceutical Executive, summarized the trend: "The reality today is that Chinese innovation is bringing genuinely new molecules and modalities to market, and global players are taking note."

GSK's mRNA Flu Vaccine Advances to Phase III

What did GSK announce?

GSK is advancing its mRNA seasonal influenza vaccine candidate, FLUm3HA.b-3NA, into a Phase III efficacy trial beginning in September 2026. The decision is based on positive Phase II data presented at the Options XIII Conference for the Control of Influenza, where the candidate demonstrated higher immune responses against all influenza strains compared with licensed standard-dose and high-dose inactivated flu vaccines in both younger and older adults.

What makes GSK's vaccine different from Moderna's approved mFLUSIVA?

The planned Phase III trial will be the first for an mRNA flu vaccine designed to target both hemagglutinin and neuraminidase — the two primary surface antigens involved in flu virus binding and spread. Moderna's mFLUSIVA, which received FDA approval earlier this year, targets HA alone. Growing evidence suggests dual HA and NA targeting could improve protection, reduce illness severity, and limit transmission beyond what HA-targeting alone achieves.

What did the Phase II data show?

The Flu-028 Phase II trial randomized 971 adults ages 18 and older across two age groups to receive either FLUm3HA.b-3NA, a non-optimized comparator candidate, or licensed age-appropriate vaccines. GSK's optimized candidate demonstrated robust immune responses to HA and NA from both influenza A and B strains in younger and older adults, with acceptable reactogenicity and safety profiles. FDA granted the candidate Fast Track designation in July 2026.

Nine More Companies Join the MFN Program

Who are the nine new companies?

The Trump administration announced MFN pricing agreements with Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The nine companies are mid-sized pharmaceutical manufacturers, and their addition brings the total number of MFN signatories to 26 — a group the administration says now covers 89% of the branded drug market.

What diseases are covered?

The agreements are expected to reduce prices on drugs treating hemophilia, Parkinson's disease, macular degeneration, glaucoma, liver disease, skin conditions, and various forms of cancer, according to the White House.

What are the manufacturers committing to beyond pricing?

The nine companies collectively committed to invest at least $19.6 billion in US manufacturing. Several are also donating active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve. UCB is contributing 163 tons of levetiracetam, Sun Pharma is contributing 71.4 tons of clindamycin and 6.75 tons of doxycycline, Teva is contributing 45 metric tons of metronidazole and 4.8 tons of amlodipine, and Astellas is contributing 25 kilograms of tacrolimus.

Does this affect patients' out-of-pocket costs?

Not directly, at least for Medicaid patients. ADVI's Lindsay Bealor Greenleaf, who spoke with Pharmaceutical Executive, explained: "Patient out-of-pocket costs in Medicaid are not much of an issue. Typically, patients are paying anywhere between $4 and $8 at the pharmacy counter for their prescription drugs. In the Medicaid program with these voluntary deals, the impact is felt squarely on the manufacturers specifically."

What comes next?

All 17 companies originally contacted by President Trump have now signed MFN deals, and the program has expanded to 26 total signatories. President Trump is also calling on Congress to enact the Great Healthcare Plan, a broader legislative proposal covering drug prices, insurance premiums, and price transparency — a push whose outcome rests with lawmakers rather than the manufacturer-by-manufacturer voluntary agreements the administration has relied on to date.

Lilly Acquires Merida Biosciences for Up to $2.875 Billion

What is Merida developing?

Merida Biosciences develops biologics engineered to selectively degrade pathogenic autoantibodies — the disease-causing agents behind a range of immune-mediated conditions — rather than broadly suppressing the immune system as many current therapies do.

What is MER511 and what does it target?

MER511 is Merida's lead program, currently in Phase I development for Graves' disease and thyroid eye disease. Both conditions are driven by thyroid-stimulating immunoglobulins — autoantibodies that activate the thyroid-stimulating hormone receptor. Graves' disease affects approximately 3 million people in the US and carries elevated cardiovascular risk and mortality, with 25% to 40% of patients going on to develop thyroid eye disease. While approved treatments exist for both conditions, none directly target the autoantibodies that cause them.

Why does this approach matter beyond the lead indication?

Merida's platform is designed to be applicable across a broad range of antibody-driven diseases. Its pipeline includes MER769, a preclinical program focused on food allergy, asthma, and chronic spontaneous urticaria, along with earlier-stage programs in kidney diseases including membranous nephropathy and other immune-mediated conditions.

How does this fit into Lilly's broader immunology strategy?

The Merida acquisition is part of a sustained pattern of precision immunology investment by Lilly in 2026. The company also acquired Ventyx Biosciences for $1.2 billion to add oral NLRP3 inhibitors, entered an $8.5 billion collaboration with Innovent and acquired Orna Therapeutics for in vivo CAR-T approaches to B-cell autoimmune diseases, and entered a $1.9 billion collaboration with Repertoire Immune Medicines on tolerizing therapies. Together these moves reflect a deliberate strategy to build a multi-mechanism precision immunology franchise that targets the biological drivers of immune-mediated disease rather than their downstream effects.